Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CPRX Stock Forecast 2025-2026
$22.80
Current Price
$2.80B
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CPRX Price Targets
+75.4%
To High Target of $40.00
+53.5%
To Median Target of $35.00
+40.4%
To Low Target of $32.00
CPRX Price Momentum
-1.2%
1 Week Change
-1.3%
1 Month Change
+3.8%
1 Year Change
+9.2%
Year-to-Date Change
-14.2%
From 52W High of $26.58
+19.7%
From 52W Low of $19.05
📊 TOP ANALYST CALLS
Did CPRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Catalyst Pharma is one of their latest high-conviction picks.
Latest CPRX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CPRX has a bullish consensus with a median price target of $35.00 (ranging from $32.00 to $40.00). The overall analyst rating is N/A (N/A/10). Currently trading at $22.80, the median forecast implies a 53.5% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 40.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CPRX Analyst Ratings
6
Buy
0
Hold
0
Sell
CPRX Price Target Range
Low
$32.00
Average
$35.00
High
$40.00
Current: $22.80
Latest CPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CPRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $33.00 |
| Mar 3, 2025 | Baird | Joel Beatty | Outperform | Maintains | $32.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Feb 27, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Reiterates | $33.00 |
| Feb 4, 2025 | Baird | Joel Beatty | Outperform | Initiates | $28.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Jan 9, 2025 | B of A Securities | Jason Gerberry | Buy | Reiterates | $30.00 |
| Nov 18, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Initiates | $35.00 |
| Nov 11, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $36.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $30.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $30.00 |
| Aug 9, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $30.00 |
| Aug 9, 2024 | Citigroup | Samantha Semenkow | Buy | Maintains | $31.00 |
| Jun 6, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $29.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $26.00 |
| May 10, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $26.00 |
| Mar 27, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $29.00 |
| Mar 22, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $34.00 |
| Mar 14, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $34.00 |
| Mar 14, 2024 | Citigroup | Samantha Semenkow | Buy | Initiates | $27.00 |
Catalyst Pharmaceuticals Inc. (CPRX) Competitors
The following stocks are similar to Catalyst Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Catalyst Pharmaceuticals Inc. (CPRX) Financial Data
Catalyst Pharmaceuticals Inc. has a market capitalization of $2.80B with a P/E ratio of 13.2x. The company generates $578.20M in trailing twelve-month revenue with a 37.6% profit margin.
Revenue growth is +15.3% quarter-over-quarter, while maintaining an operating margin of +44.7% and return on equity of +27.5%.
Valuation Metrics
Market Cap
$2.80B
Enterprise Value
$2.16B
P/E Ratio
13.2x
PEG Ratio
0.8x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
+15.3%
Gross Margin
+84.7%
Operating Margin
+44.7%
Net Margin
+37.6%
EPS Growth
+20.3%
Financial Health
Cash/Price Ratio
+24.6%
Current Ratio
6.6x
Debt/Equity
0.3x
ROE
+27.5%
ROA
+17.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Catalyst Pharmaceuticals Inc. (CPRX) Business Model
About Catalyst Pharmaceuticals Inc.
What They Do
Develops therapies for rare neurological diseases.
Business Model
Catalyst Pharmaceuticals focuses on developing and commercializing innovative therapies for rare neurological diseases. The company primarily generates revenue through the sale of its flagship treatment for Lambert-Eaton myasthenic syndrome (LEMS) and aims to address unmet medical needs in niche markets.
Additional Information
Headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals is committed to enhancing the quality of life for patients with rare neuromuscular disorders. The company actively seeks to advance its pipeline and foster collaborations in the medical and scientific communities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
181
CEO
Mr. Richard John Daly M.B.A.
Country
United States
IPO Year
2006
Website
catalystpharma.comCatalyst Pharmaceuticals Inc. (CPRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dec 09, 2025
By Zacks Equity Research
Tale of the Tape
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 05, 2025
By Zacks Equity Research
Realtime BLOG
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Dec 04, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Catalyst Pharmaceuticals, Inc. (CPRX) presented at the BofA Securities CNS Therapeutics Virtual Conference, discussing its developments and strategies in the CNS therapeutics sector.
Why It Matters
Catalyst Pharmaceuticals' presentation at a major conference could indicate upcoming developments or partnerships, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Catalyst (CPRX) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for insights into stock performance.
Why It Matters
Catalyst's recent earnings report can influence stock performance, impacting investor sentiment and future price movements based on financial health and market expectations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Catalyst Pharmaceutical (CPRX) has reached a key support level and surpassed the 20-day moving average, indicating a potential short-term bullish trend.
Why It Matters
Catalyst Pharmaceutical's recent support level and movement above the 20-day moving average indicate potential short-term gains, signaling a bullish trend that may attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Catalyst Pharmaceuticals, Inc. (CPRX) presented at the Citi Annual Global Healthcare Conference 2025, highlighting its developments and strategies to investors.
Why It Matters
Catalyst Pharmaceuticals' presentation at a major healthcare conference highlights its growth potential and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks emphasizes its Rank system based on earnings estimates and revisions to identify strong stocks, while also monitoring value, growth, and momentum trends.
Why It Matters
Zacks' emphasis on earnings estimates and revisions highlights potential stock performance, guiding investors toward high-quality picks amid evolving market trends.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet
10 days ago
Quick Summary
Analysts' price targets suggest a 47.4% upside for Catalyst (CPRX). There is strong consensus on raised earnings estimates, indicating potential stock growth.
Why It Matters
Analysts' price targets suggest significant upside for Catalyst (CPRX), indicating potential for growth. Consensus on rising earnings estimates further supports positive sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CPRX Stock
What is Catalyst Pharmaceuticals Inc.'s (CPRX) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Catalyst Pharmaceuticals Inc. (CPRX) has a median price target of $35.00. The highest price target is $40.00 and the lowest is $32.00.
Is CPRX stock a good investment in 2026?
According to current analyst ratings, CPRX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CPRX stock?
Wall Street analysts predict CPRX stock could reach $35.00 in the next 12 months. This represents a 53.5% increase from the current price of $22.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Catalyst Pharmaceuticals Inc.'s business model?
Catalyst Pharmaceuticals focuses on developing and commercializing innovative therapies for rare neurological diseases. The company primarily generates revenue through the sale of its flagship treatment for Lambert-Eaton myasthenic syndrome (LEMS) and aims to address unmet medical needs in niche markets.
What is the highest forecasted price for CPRX Catalyst Pharmaceuticals Inc.?
The highest price target for CPRX is $40.00 from at , which represents a 75.4% increase from the current price of $22.80.
What is the lowest forecasted price for CPRX Catalyst Pharmaceuticals Inc.?
The lowest price target for CPRX is $32.00 from Joel Beatty at Baird, which represents a 40.4% increase from the current price of $22.80.
What is the overall CPRX consensus from analysts for Catalyst Pharmaceuticals Inc.?
The overall analyst consensus for CPRX is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are CPRX stock price projections?
Stock price projections, including those for Catalyst Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 8:45 AM UTC